balixafortide

Balixafortide is a potent, selective, and reversible macrocyclic peptide antagonist of the C-X-C chemokine receptor type 4 (CXCR4). By binding to CXCR4, it prevents the interaction with its ligand stromal derived factor 1 (SDF-1 or CXCL12), thereby inhibiting receptor activation. This mechanism leads to mobilization of hematopoietic stem and progenitor cells from bone marrow into peripheral blood. Balixafortide has been investigated primarily for oncology indications such as metastatic breast cancer (notably HER2-negative disease), but also in other therapeutic areas including stem cell mobilization, myocardial infarction, adenocarcinoma, kidney disorders, and preclinical studies for COVID-19 due to observed anti-inflammatory and antiviral effects. The drug was originally developed by Polyphor and is now being advanced by Spexis; rights in China have been partnered with Fosun Pharma[1][2][4][7].

Other names

balixafortide [INN]balixafortide [USAN]